|
|
|
|
||
Re: Davy report I can see a scenario whereby Elan trials D-5 in the U.S. to keep costs down as much as possible and if successful sells the ROW rights which would allow them to build the infrastructure necessary to market D-5 if they want to keep all of the product outside of the committed royalties. There are some interesting possibilities. |
return to message board, top of board |